{
  "id": 7815501,
  "title": "Sling banks $123M for an experimental thyroid eye disease pill",
  "url": "https://urgent.news/2026/09/16/sling-banks-123m-for-an-experimental-thyroid-eye-disease-pill",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-16T14:54:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/sling-linsitinib-series-c-financing-thyroid-eye-disease/830452/"
  },
  "original_language": "en",
  "account": null,
  "summary": "A confirmatory late-stage study is now also underway for what the startup is positioning as, potentially, the first oral alternative to approved injectables like Amgen's Tepezza and Viridian's Lumvoa.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}